First In Ventures

ZeroTier offers a software-defined networking solution that enables users to create private networks connecting multiple devices globally. The platform supports direct peer-to-peer connections, ensures data privacy through end-to-end encryption, and is compatible with various operating systems.

Antithesis is a United States-based company that specializes in quality assurance software aimed at enhancing software reliability testing. The company's cloud platform automates this process by simulating environments that do not impact production systems. By continuously analyzing software behavior, Antithesis detects issues and reproduces problems in a fully deterministic setting. The platform introduces various faults, such as network retries and thread hangs, to identify rare errors and explore multiple outcomes. Furthermore, developers can test software under diverse conditions, specify validation properties, and trace issues back to their root causes. Antithesis facilitates efficient debugging by offering detailed tracking of system states and the capability to replay every moment leading to an issue, ultimately enabling clients to detect failures that occur under specific network, hardware, or timing conditions.

Pluton Biosciences discovers and tests microbes to develop products such as pesticides and pharmaceuticals. Its platform mines and clones microbes to create biopesticides, crop protection solutions, human health products, and bioremediation agents.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

Yali Biosciences is a food tech company focused on utilizing synthetic biology and genomics to develop climate-smart and sustainable food options. The company operates a synthetic biology platform that leverages computational biology to design and produce specialized fats aimed at enhancing alternative dairy products. By prioritizing renewable resources, Yali Biosciences enables the food industry to create delicious and sustainable alternatives to traditional dairy, contributing to ecological responsibility within the sector.

AarogyaAI is an artificial intelligence driven software as a service that diagnoses drug-resistant infections, including drug-resistant tuberculosis. It accepts a patient's DNA sequence via a cloud-based platform and, using machine-learning algorithms, provides a comprehensive drug susceptibility report within hours, enabling healthcare providers to select effective treatment options and drug combinations promptly.

Founded in 2016, Adlumin operates a security automation platform designed to detect threats, malfunctions, and IT failures. Its platform collects and analyzes data from various sources, offering features like One-Touch Compliance Reporting for financial auditors. The company empowers organizations with advanced technology and expert guidance for proactive cybersecurity and efficient IT operations.

MEDiC is a biotechnology company based in the San Francisco Bay Area. It specializes in cancer drug target discovery using its proprietary CRISPR functional genomics platform, focusing on 3D tumor models.

Pluton Biosciences discovers and tests microbes to develop products such as pesticides and pharmaceuticals. Its platform mines and clones microbes to create biopesticides, crop protection solutions, human health products, and bioremediation agents.

Gliknik Inc. is a biopharmaceutical company focused on developing therapies for patients with cancer and immune disorders. Founded in 2007 and based in Baltimore, Maryland, Gliknik's product portfolio includes GL-0817, aimed at preventing the recurrence of squamous cell carcinoma of the oral cavity, and GL-2045, which targets various autoimmune diseases such as immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Myasthenia gravis. Additionally, the company develops GB-4542, an anti-CD20 monoclonal antibody therapy. Gliknik employs several innovative platforms, including an Immunomodulator Platform that utilizes off-the-shelf peptide drugs to enhance immune responses against cancer, the Stradomer Platform that creates drugs mimicking the efficacy of human intravenous immunoglobulin, and the Stradobody Platform, which produces compounds akin to monoclonal antibodies for tumor cell targeting. Through these initiatives, Gliknik aims to provide meaningful therapies that alleviate suffering for patients facing these challenging health conditions.

4baseCare is a company specializing in precision oncology solutions that utilize advanced genomic technologies to enhance cancer treatment. By analyzing the genetic profiles of patients, 4baseCare aims to identify targeted therapies that are both more effective and less harmful than conventional treatments. The company offers a range of services, including genomic testing, data interpretation, and personalized treatment recommendations, all designed to improve patient outcomes. Additionally, 4baseCare fosters collaborations with hospitals, research institutions, and pharmaceutical companies to advance cancer care and research. Their technology supports a patient-centric ecosystem, contributing to a curated database of genetic and clinical outcome information, thereby facilitating precision and personalized cancer treatments.

MultiplAI Health leverages genomics and AI to provide universal remote screening for cardiovascular diseases and other complex diseases. It uses a liquid biopsy of whole blood based on RNA sequencing and deep learning, creating a comprehensive biomarker test for early disease detection. The test is administered remotely using only a simple blood sample, making it affordable and accessible for preventative screening and post-treatment monitoring.

Parallel Health is a skin health company that uses genomics, the skin microbiome, and machine learning to offer end-to-end dermatology solutions. It develops a precision health platform that combines microbial genomics, big data, and AI to enable skin testing, personalized microbiome products, and custom prescriptions for consumers, patients, and clinicians, integrating derm telehealth, microbiome diagnostics, and data-driven skincare therapies to address diverse skin conditions with tailored treatments.

Mammoth Cyber specializes in computer and network security. It develops an agentless zero-trust access system that safeguards remote, data, and web access while providing full visibility and control over user interactions with applications.

Lassogen, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, California. The company focuses on the development of lasso peptides as a novel therapeutic modality aimed at addressing complex health challenges. Lassogen's research targets difficult receptors and encompasses a range of applications, including cancer treatment, autoimmunity, pain and inflammation management, as well as therapies for diseases associated with G protein-coupled receptors and ion channels. By leveraging advancements in synthetic biology, Lassogen seeks to unlock the potential of lasso peptides to create innovative medicines that can effectively diagnose and treat various conditions.

AarogyaAI is an artificial intelligence driven software as a service that diagnoses drug-resistant infections, including drug-resistant tuberculosis. It accepts a patient's DNA sequence via a cloud-based platform and, using machine-learning algorithms, provides a comprehensive drug susceptibility report within hours, enabling healthcare providers to select effective treatment options and drug combinations promptly.